Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreBOSTON, MA, August 5, 2024 – OrthoSpineNews – NanoHive Medical, a leader in 3D-printed titanium spinal interbody fusion devices, announces a $7M Series C Financing to...
Read MoreROCKVILLE, Md., July 29, 2024 /PRNewswire/ — Maxim Biomedical, Inc., one of the nation’s leading end-to-end rapid diagnostic test developers and manufacturers, has received a new minority...
Read MoreMacroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreTFF Pharmaceuticals, Inc. announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.
Read MoreCompanies need to have a clear, stable business model in terms of who pays for what, he notes, and it helps to establish an ongoing relationship with a payor and/or provider.
Read MoreDr. Glezer’s appointment as Managing Director will strengthen Outcome’s healthcare innovation and product launch expertise. BOSTON–Outcome Capital, LLC, a highly specialized life sciences and healthcare...
Read MoreBOSTON–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Peter F. Meyer, Ph.D. has been appointed as...
Read MorePlease join us in congratulating them on their new roles.
Read MoreOutcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read...
Read MoreBOSTON — Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted...
Read MoreOutcome Capital is a strategic advisor to Peterson Companies, majority shareholder of Propella Boston – December 28, 2023 — Outcome Capital, a highly specialized life sciences...
Read MoreBoston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a...
Read MoreAthersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into...
Read MoreThe collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai...
Read MoreOutcome Capital is Top 10 Life Science Financial Provider for 2023 awarded by Life Science Review July 20, 2023 Read the full article here:
Read MoreCollaboration will support early childhood education programs and address early childhood teacher retention. July 13, 2023 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a...
Read MoreOutcome Capital Named Top 10 M&A Consulting Firms December 1, 2022 Outcome Capital leads in Financial Services Review annual listing of 10 companies that are...
Read More– Advisory Services Practice to Assist Growth-Stage Life Science Companies in Pre-Transaction Preparation and Strategic Corporate Development – August 24, 2022 08:30 AM Eastern Daylight...
Read MoreBOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing...
Read MoreWould you like to learn more about working with Outcome Capital or discuss your specific needs?